Exploring the discrepancies between clinical trials and real-world data by accounting for *Selection criteria, Operations,* and *Measurements of Outcome*

Luca Marzano*[a], Adam S. Darwich[a], Asaf Dan[b], Salomon Tendler[bc],
Rolf Lewensohn[b], Luigi De Petris[b], Jayanth Raghothama[a],
Sebastiaan Meijer[a]

*Corresponding author: Luca Marzano, Hälsovägen 11 C
141 57 Huddinge (Sweden), lmarzano@kth.se*

*[a]Division of Health Informatics and Logistics, School of Engineering Sciences in
Chemistry, Biotechnology and Health (CBH), KTH Royal Institute of
Technology,
Stockholm, Sweden
[b]Dept. of Oncology-Pathology, Karolinska Institutet and the Thoracic Oncology
Center, Karolinska University hospital, Stockholm, Sweden
[c]Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY*

Conflict of interest statement
The authors declare no competing interests for this work.

Funding Information
The Swedish Cancer Society (grant no. CAN 2018/597 and CAN2021/1469 Pj01) to R. Lewensohn
and from the Stockholm Cancer Society (grant no. #201202 to R. Lewensohn and #174063, #201103
and #231123 to L. De Petris).

Keywords: clinical trials, oncology, trial simulation, survival analysis, population analysis,
personalized medicine, chemotherapy, cancers, biostatistics, bioinformatics

Abstract

The potential of real-world data to inform clinical trial design and supplement control arms has gained
much interest in recent years. The most common approach relies on reproducing control arm
outcomes by matching real-world patient cohorts to clinical trial baseline populations. However,
recent studies pointed out that there is a lack of replicability, generalisability, and consensus. Further,
few studies consider differences in operational processes. Discovering and accounting for
confounders, including hidden effects related to the treatment process and clinical trial study protocol,
would potentially allow for improved translation between clinical trials and real-world data.
In this paper, we propose an approach that aims to explore and examine these confounders by
investigating the impact of selection criteria and operations on the measurements of outcome. We
tested the approach on a dataset consisting of small cell lung cancer patients receiving platinum-based
chemotherapy regimens from a real-world data cohort (n=223) and six clinical trial control arms
(n=1,224).
The results showed that the discrepancy between real-world and clinical trial data potentially depends
on differences in both patient populations and operational conditions (*e.g.*, frequency of assessments,
and censoring), for which further investigation is required.
The outcomes of this work suggest areas of improvement for systematically exploring and accounting
for differences in outcomes between study cohorts. Continued development of the method presented
here could pave the way for transferring learning across clinical studies and developing mutual
translation between the real-world and clinical trials to inform clinical study design.

Introduction

During the past few years discussions have highlighted the limitations of randomised clinical trials (RCTs) due to their high costs and the challenge of translating clinical outcomes between RCT cohorts and real-world patient populations[1,2]. Since the 21st Century Cures Act in 2015, the potential for translating between real-world data (RWD) and clinical trials to inform regulatory decision-making has gained attention[3–7]. A growing body of research has focused on the extrapolation of RWD to inform clinical trial design, often described as emulation of RCT control arms or simulated (synthetic) data[8–12], with the purpose of reproducing clinical trial outcomes[8–11,13–17].

In an attempt to adjust for confounders, analyses have often focused on recreating the inclusion criteria of clinical trials in RWD cohorts[8–10,14,16,18–26]. The most common method is patient matching based on propensity score[27]. Propensity score is formally defined by Rosenbaum and Rubin as the conditional probability of assignment to a particular treatment[28]. The method gives a probability of an RWD patient being enrolled in a clinical trial study arm given a vector of observed covariates. Then, the RWD cohort is adjusted by including only patients with high propensity scores. Propensity score approaches, including variations of this method, still constitute the main proposed technique for adjusting for confounders in RWD cohorts based on the characteristics of RCT control arms[8,10,16,19,21,22,24,26,29,30].

However, propensity score approaches have been shown to be limited in this aspect since a probabilistic empirical approach is highly sensitive to undetected confounders and biases of the data[1,8,10,11,14,25]. Indeed, alignment of patient characteristics is seldom sufficient to reproduce outcomes across populations[10,11,16]. It has repeatedly been pointed out that there is a lack of replicability and generalisability[1,9,10,13,17] with only few clinical trials being replicable based on RWD[10,13,17]. Results have been mixed depending on the specific case study[13,17,31] and measurements of outcome[10,16] (*e.g.*, overall survival and intermediate endpoints[10,14]).
The lack of translatability has been attributed to the differences in populations, such as baseline confounders and key eligibility criteria that are not available in the data[10,11,13,14]. The main focus of improvement has been on how patient demographics affect measurements of outcome with little focus on the operations and processes behind the data[8,10,13,23,32]. The potential operational differences between clinical practice and clinical trial protocols have been mentioned as potential confounders but are yet to be fully explored[1,2,8,10,11,32]. There is a need to investigate the bias that is introduced by differences in investigation and clinical assessment[1,10,11,23,32] (*e.g.*, lack of pre-trial monitoring in clinical practice[1]), and potential differences in the RCT monitoring process compared to real-world patients, with more detailed and potentially more frequent follow-up on tumour response and adverse effects, and decision-making such as withdrawal of therapy[1,10,11,25,32].

Translation between clinical trials and real-world populations is therefore still not completely understood[1,8–10,13,14,16,17]. Further refinement of proposed methodologies are required to realise the potential of RWD to inform clinical trial design[6,9,10,13,33]. In the past, the added value of a mechanistic systems view of translation in drug development has been beneficial for other areas of model-informed drug development, such as quantitative *in vitro-in vivo* extrapolation and physiologically-based pharmacokinetics of metabolic drug-drug interactions[34]. Developing systems approaches for real-world evidence could enable a similar learn-confirm cycle and learning across studies, where the represented systems include not only the patient, disease and treatment, but also the operational context[35].

In this paper we propose an approach that aims to systematically explore the discrepancies between RWD and RCTs by discovering and accounting for the differences in population samples (randomisation) and operation (protocols and clinical practice). We abbreviate the approach as SOMO as it is based on exploring the effects of Selection Criteria (S), Operations (O) and study protocols, on

99   the replication of the Measurements of Outcome (MO). We developed and tested the SOMO approach
100 using RCTs and RWD on extensive-disease (ED) small cell lung cancer (SCLC) patients receiving
101 platinum etoposide chemotherapy. This was done to the extent it was possible given the available
102 information, many factors were determined to be known unknowns.

Methods

The SOMO approach

Figure 1 shows the SOMO approach and the accompanying data analysis that was carried out. In
short, the analysis included the following components:

(S). Selection Criteria refers to all aspects related to the baseline variables that define the population,
the biology of the disease, and the inclusion and exclusion criteria of the clinical datasets.

(O). Operations and study protocols refer to aspects related to operational processes (or
mechanisms) occurring during treatment. These can be grouped into longitudinal disease factors (*e.g.*,
tumour progression), the study protocol operations (*e.g.*, removal and censoring of patients that did
not adhere to the study protocol), or to the potential differences from the real-world routine healthcare
operations (*e.g.*, adjustment of doses, change of treatment due to relapse, patients opting to not receive
treatment).

(MO). Measurements of Outcome refer to the metrics used to evaluate treatment efficacy (and
safety, when available) and estimation of the feasibility of translation between RWD and RCTs using
a comparative approach. These can be one or multiple outcomes depending on the study endpoints
and the statistical analysis defined by the protocol (*e.g.*, overall survival, progress free survival,
toxicity, exposure, or overall response, *etc.*), as well as and the available information from the real-
world cohort.

Available RCT and RWD data are retrieved, pre-processed, and harmonised into a combined dataset.
Then, clinical experts interpret and contextualise information (Figure 1, steps a.1-2). The analysis is
then carried out in the following steps:

- **Explorative analysis.** An exploratory data analysis is performed to define the SOMO
  components (steps b.1-5). During this phase outcomes, relevant available factors, and
  potentially important missing aspects, are mapped into the three categories as detailed below.
  First, the comparison between RCTs and RWD outcomes is carried out to estimate baseline
  differences in measurements of outcome between cohorts. Then, a comparison between the
  two populations is performed to detect any potential mismatch between patient covariates due
  to selection and randomisation. Finally, for the operational aspects, potential confounders are
  investigated through comparison between study protocols and clinical practice with the aid of
  longitudinal outcome measures (*e.g.*, Kaplan Meier or dose response curves) and clinical
  expert feedback.

- **Estimating the impact of factors on the discrepancies in outcomes between cohorts.** The
  potential impact of selection criteria and operations is explored by applying matching based
  on the relevant available variables and simulating effects of operations. The impact on
  measurements of outcome is then compared (steps c.1-2). Clinical expert involvement allows
  verification of the results by identifying and discussing eventual biases and confounders (step
  d).

Hence, one of the outcomes was a list of potential factors related to selection criteria and operations
that could contribute to explaining the translational gap and quantifying their effects, or indicative
future aspects to explore when the hypotheses cannot be tested due to the lack of available
information.

Case study: extensive disease small cell lung cancer patients receiving platinum-etoposide chemotherapy.

Cohort description
In this study a mixed cohort was collated, including RWD and RCTs of ED-SCLC patients that had received platinum etoposide chemotherapy as first line treatment:

- The RWD included in this analysis was part of a retrospective cohort of SCLC patients treated at Karolinska University Hospital (Stockholm, Sweden) between 2008 and 2016[36] (RWD KI, n patients=223). The study was approved by the institutional review boards at Karolinska Institutet and Stockholm County Council (2016/8-31).

- The RCT comparative groups originated from open data shared through the Project Data Sphere Initiative[37], including participants receiving the standard platinum etoposide treatment that were randomised into the control arm from three randomised phase III clinical trials: PDS_Amgen (NCT00119613, n=232), PDS_Alliance (NCT00003299, n=270), PDS_EliLilly (NCT00363415, n=370), and three phase Ib-II trials PDS_PHASE2_Alliance (NCT00453154, n=46), PDS_PHASE2_EliLilly (NCT01439568, n=41), PDS_PHASE2_G1Thera (NCT02499770, n=37). A subset of patients (n=85) of PDS_EliLilly were censored after the study was declared futile after the interim analysis. These were removed prior to the analysis.

The combined mixed cohort encompassed n=1,224 patients in total. The common patient variables were age, sex, brain metastasis (BM), Eastern Cooperative Oncology Group performance status (ECOG), the cohort from which the data were retrieved (STUDY), and the label referring to if patients originated from the RCTs or real-world cohort (STUDY_TYPE), progression-free survival (PFS), Overall Survival (OS), and eventual censoring (CENSOR). The real-world cohort had been re-staged using the 8th version of the International Association for the Study of Lung Cancer (IASLC) TNM in a previous validation study[38]. A stage variable (STAGE) was created where real-world patients were defined using TNM staging (IVA or IVB), while the random clinical trials patients were staged using the traditional Veterans' Administration Lung Study Group (VALSG) method (ED stage). A summary of the real-world data and clinical trials cohorts is reported in the Supplementary Material, Table S1.

Survival Analysis
Table 1 summarises how the SOMO approach was applied to the ED-SCLC case study. The main techniques used during the analysis were: cohort stratification given the available variables, propensity score matching with weights computed using logistic regression[27], and oversampling to generate simulated cohorts using the standard Synthetic Minority Over-sampling TEchnique-Nominal Continuous (SMOTENC) algorithm based on k-nearest neighbours[39]. Table 1 details how these techniques were used for investigating the impact of variables on the observed outcomes.

First, the RCTs were combined into one dataset and directly compared with the RWD. Then, a pairwise analysis was carried out using a simulation approach to compare the RWD with each RCT to explore the between study variability in measurements of outcome.

Differences in the survival outcomes (OS and PFS) were explored. This was done using Kaplan Meier Curves and Cox proportional Hazard ratios. The reference for computing the hazard ratios was the RWD cohort.

For the pairwise analysis, simulations were carried out creating a surrogate cohort (n=250) by randomly selecting a 1:1 ratio of patients from the two populations, the RWD and the analysed RCT (Figure S1). Then, the Cox hazard ratios between real-world and clinical trials cohorts were

computed. This was repeated 100 times to estimate the variability in the outcomes. Different scenarios
were simulated by adjusting the selection of patients according to the identified variables across the
datasets (*e.g.*, stratification by individual variables). The main assumption was that in the ideal
scenario, where we would be capable of blindly adjusting for all confounders in the RWD to RCTs,
there would be no significant differences in outcome between the two populations. Hence, assessing
the impact of the explored factors on measurements of outcome could be used for future trial designs.

Results

Mapping available data and SOMO components

In total eight selection criteria factors were identified, nine potential operational discrepancies, and
three potential effects on measurements of outcome. Among these, it was possible to study the effects
of seven selection criteria and four operational factors, on the two measurements of outcome (See
Table 1 for more details).

From the available data, it was possible to explore the effects of the commonly available variables
reported in the previous section by observing the differences in outcomes for stratified subsamples of
the cohort. The RWD stage IVA patients (n=46) were oversampled with the SMOTENC algorithm to
balance these against the IVB patients (n=231). Propensity score matching allowed the exploration of
the effects of these variables. Moreover, propensity score was used to simulate the common selection
criterion across all RCTs, patients that are expected to live more than three months, for the RWD.

The operational aspects that were possible to explore were: discrepancies in outcome definitions
(RWD survival outcomes were calculated from the start of the therapy, for RCTs this was defined from the
randomisation), the potential progression of ECOG from 2 to 3 in the RCTs as compared to the
outcomes of ECOG 3 RWD patients, and RCT censoring effects. The censoring was studied from
different perspectives: removal of all censored patients, simulating censoring in a synthetic RWD
cohort using SMOTENC sampling using the same distribution in the RCTs, and including the
censoring as a variable in the propensity score matching.

Due to lack of overlap in information across RWD and RCTs, it was not possible to investigate the
effect of blood chemistry values and biomarkers, dose administration, intermediate decisions, and
longitudinal events (tumour progression or adverse effects), and treatments after the first chemo-
cycle. Considerations regarding toxicity outcomes were not possible due to the lack of longitudinal
information. Furthermore, information on PFS was limited and only reported for a small subset of
RCT patients (mainly from PDS_EliLilly).

Cohort discrepancies

Table 2 reports the baseline discrepancies between the studies and the main results of the comparison
of RWD with the aggregated RCT data. A significant difference was observed when comparing
survival outcomes in RWD and RCT patients: OS (hazard ratio: 0.65 [0.55, 0.75], reference: RWD)
and PFS (hazard ratio: 0.70 [0.58, 0.85]). The full set of results are reported in the Supplementary
Material, Table S2.

Analysis of selection criteria identified several differences in the RWD as compared to the RCTs. In
the RWD, the age distribution was skewed towards older age (median: 70 years, range: [42-86]
years), a more balanced sex ratio (male: 43.4%, female: 56.6%), and a higher frequency of patients
with ECOG 2 (n=68, 29.8%; Table S1). Baseline brain metastasis records were not available for all
clinical trial patients, or not explicit mentioned as an exclusion criterion (*e.g.*, PDS_Alliance).

The analysis of operational aspects highlighted differences in the censoring between the two settings.
Real-world censoring corresponded to a few patients (n=5) with long survival (subject to right
censoring). For trial patients censoring occurred with higher frequency (i.e., n=225, 60.8% in
PDS_EliLilly) across the survival range of 0-300 days. This resulted in higher estimates of OS in the
RCTs compared to the RWD (Figure 2a).

Selection Criteria: Performance Status and TNM Staging

The subcohorts of patients that showed similar OS across the two cohorts (i.e., hazard ratios not statistically different from 1) were ECOG 2 patients (Table 2), and RWD patients with TNM staging IVA, using both conventional stratification and SMOTENC (Table 2 and Figure S2). Traditional propensity score matching did not overcome the difference in OS between the two cohorts (hazard ratio: 0.55 [0.44, 0.70]; Table S1).

For what concerns PFS, the outcomes were similar for the RCTs and RWD cohort across ECOG subgroups, TNM IVA cancer staging of RWD patients using conventional stratification and with SMOTENC oversampling, and traditional propensity score matching (Table 2).

Operations: the effect of RCT censoring on survival estimation and propensity score matching

The effect of operational aspects could be deduced from the comparison of the survival curve shapes. Figure 2a shows that the differing shapes of the Kaplan Meier curve between the two cohorts (*i.e.*, lower survival in the first 30 days for the RCTs, followed by a higher survival for RCTs until 130 days before reaching a similar trend for the rest of the longitudinal curve).

The high RCT censoring was a key operational aspect that was impacting on the survival discrepancies. In fact, the higher survival in the RCTs during the first 130 days was strongly related to the censoring (Figure 2a), where removing the censored patients or simulating the same censoring distribution in the RWD synthetic cohort reduced the difference in overall survival (Figure 2b and Table S1).

Moreover, adjusting the propensity score by matching the censoring operations allowed to reduce the discrepancy in OS between RCTs and RWD (Figure 3). In contrast, PFS was higher in the RWD compared to RCT cohort when correcting for censoring (hazard ratio: 1.5 [1.2, 1.8]) (Table 2).

The lower OS in the RCTs during the first 30 days could be related to potential progression of baseline ECOG 2 between the time of screening and randomisation in the RCTs. In fact, Figure S3 shows that ECOG 2 patients in RCTs have similar OS as compared to ECOG 3 patients from the RWD (n=47) in the range of 0 to 30 days, and identical PFS curve.

Pairwise randomised controlled trial comparison to the real-world population

Figures 4 and 5 show the OS of PDS_EliLilly and PDS_Amgen, and PFS for PDS_EliLilly following simulation-based oversampling of subgroups. Figure S4 shows the OS for PDS_Alliance and the aggregated cohort of Phase I-II patients following simulation-based oversampling. Overall, the results confirmed the findings of the aggregated RCT analysis (Table S2). In addition, this allowed us to investigate the variability between the RCTs and the impact of correcting for the known discrepancies between the RCTs and RWD.

Oversampling of stage IVA patients in RWD played a role in reducing the discrepancies in OS across all the trials. Similarly, this improved the discrepancy in PFS for the PDS_EliLilly trial. For the trials with a relevant number of censored patients (i.e., 60% for PDS_EliLilly, 18.28% for the Phase I/II aggregated cohort), censoring was the most impactful factor and was associated with a larger difference in OS at baseline.

Figure 5 underlines the impact of operations on PFS, from which similar outcomes were achieved when correcting for ECOG and TNM stage. Instead, when correcting for censoring alone the discrepancy in PFS between PDS_EliLilly and the RWD was increased, with a. higher PFS in the RWD cohort.

Discussion

In this study, we developed and tested an approach that aims to explore and estimate the impact of selection criteria and operations on outcome replication between RWD and RCTs. This was done using a systematic approach, attempting to account for known differences in the population samples.

Previous real-world evidence studies of lung cancer have mainly focused on non-small cell lung cancer, thus leaving small cell lung cancer understudied[40]. To the best of the authors' knowledge, this is the most comprehensive real-world evidence study for small cell lung cancer disease. Analyses of selection criteria and measurements of outcome showed comparable results to previous studies, where a larger difference was observed in overall survival between RCTs and RWD compared to other intermediate endpoints[10,14]. Further, population differences were observed in age, an under-representation of ECOG 2 and higher representation of females in the RWD as compared to the clinical trials[41–43].

The similarity between the stage IVA real-world patients and the clinical trial patients presented an interesting aspect. The 8th TNM staging (with sub-categorisation of ED-SCLC patients in IVA and IVB stages) was not yet developed when the trials were executed, and the LD/ED staging is still largely used to define treatment intention[38]. Previous studies have pointed out significant differences in survival between IVA and IVB patients[38,44–46]. This result may be due to selection bias in RCTs, favouring younger patients with comparably better overall health and lower disease burden, which is only partially captured by the TNM staging. However, the low sample size of IVA patients in the real-world cohort is a source of potential bias and further investigation would be needed to confirm this.

The results of our work are also relevant from the general perspectives on how to improve future clinical trial design. For example, censoring in clinical trials is a known potential confounder[47]. This work underlined that this was a key operational factor with a relatively high impact, thus leading to a potential overestimation of overall survival in clinical trials (Table 2, Figure 2-3). Moreover, when censored patients were removed, other variables reported in Table S2 reduced the difference in OS between the RCTs and RWD. Thus, indicating how the censoring could bias the estimated difference in OS between the cohorts. Moreover, the interventions we applied to assess censoring effect were useful as a retrospective correction of the outcomes, but not applicable as prospective prior RWD-RCT translation.

As shown in Figure S3, ECOG 2 RCT patients showed more similar OS and PFS to ECOG 3 RWD patients. This could potentially be explained by differences in patient condition between the pre-trial phase and randomisation that could lead to worsening in baseline ECOG.

The results showed that the challenge of replicating outcomes in clinical trials from RWD patients depend not only on patient characteristics discrepancies, but also on differences in operations. This can be seen in Figures 2, 5 and S3 where the survival curves of the RCTs and RWD patients present differences in OS, potential due to operational differences in follow-up. This is underlined by the PFS analysis, where matching of population variables (performance status and TNM staging) resulted in indistinguishable PFS between RCTs and RWD. However, the discrepancy in PFS war larger when accounting for the censoring (Table 2 and Figure 5). This result is surprising, and we suspect it could be due to more frequent monitoring of clinical trial patients that could result in a shorter reported progression-free survival when adverse events or relapse occur.

In previous works, the dominant approach has been the propensity score informed by clinical trial data[10,24–26,30,31,46]. No in-depth examination of differences in operations has been done before. Figure 3 demonstrates the relevant contribution operations (i.e., censoring) to biasing propensity score matching. This can potentially explain why replication was not achieved in previous works. Indeed, in the ideal condition of having two populations with the same support of baseline covariates and sufficient population sample, accounting for the eventual operational differences, should theoretically

364   account for any misalignment in study outcomes [9,11,31,46]. One limitation of the propensity score is that
365   it works from only one direction by selecting RWD patients that match RCTs, thus not accounting for
366   any additional findings and confounders that are only detectable in the RWD population. This
367   approach is limited for prospective applications since it would blindly work only in the scenario
368   where all relevant confounders are accounted for in the RCTs.
369
RWD can inform additional disparities between RCTs and clinical practice[1]. Previous studies indicate
that this difference is consistent and independent of the studied case[9,9,10,13,17]. One of the observations
in this study related to the time-dynamic differences in Kaplan Meier curves between RCTs and RWD
(Figure 2). Similar Kaplan Meier curves as in Figure 2a have previously been found in other oncology
case studies[10,14], thus suggesting that the impact of operations is not isolated only to small cell lung
cancer. Further research is needed to understand the origins of this difference[35]. It has been noted that
in translating between RCTs and RWD, understanding the complexity of clinical practice and
treatment processes may be instrumental to explaining this[35].
378
The SOMO approach aims to contribute to the research direction on establishing an analytical process
to estimate the challenging trade-off between internal validity and generalizability[6,11,13,33]. In this work
we proposed how such a framework could be beneficial for both translational directions: clinical trials
can be improved by understanding the discrepancy with the real-world, and real-world therapies can
be leveraged by comparing the discrepancies of trials from the real-world (*e.g.*, Figure 4 and Figure
S4).
385
We are not claiming to have developed a definitive approach, as this work shows we identified several
factors that were not possible to account for due to the lack of overlapping information. However, we
believe that further development of the general method will allow for learning across translational
activities. This may contribute to building regulatory acceptance in the real-world evidence approach
over time as has been the case with other mechanistic modelling efforts (*e.g.*, metabolic drug-drug
interaction predictions[34,48]). This is a first attempt at trying to push the real-world evidence paradigm
into a similar learn-confirm cycle from which we learn case by case and pragmatically improve the
usage of real-world data in future clinical trials.
394
The work presents some limitations to be address in the future research. There are still a set of key
hypotheses reported in Table 1 that were not possible to address in the present study. The RWD
represented only a single centre and lacked longitudinal variables (e.g., tumour progression, doses,
and adverse effects). To address these issues, the collection of these variables and the extensive
collection of data is being performed. Expansion of RWD patient cohort trough national cancer
registries is the next step of the analysis. Moreover, SOMO was tested on small cell lung cancer, and
research on other case studies would be beneficial to increase the generalizability of the work. In this
study, the experts involved represented the clinical side of the real-world domain. In the future, we
will explore the involvement of experts on clinical trial in oncology and regulatory agencies.
404
405   The increasing presence of RWD in clinical trial studies constitute a natural step for regulatory
406   decision and future study designs. Improving upon approaches such as SOMO would pave the way to
407   understand how we can use real-world data to close the gap between internal validity and
408   generalizability of clinical trials.
409

Study Highlights

What is the current knowledge on the topic?
Real-world data have the potential to inform clinical trial design, control arms, and regulatory
assessment. However, real-world evidence studies have shown poor replication and generalizability
and a lack of consensus on the analytical process, thus underlining that the mechanisms that would
allow the translation between clinical trials and real-world populations are still not completely
understood.

What question did this study address?
What are the mechanisms that would allow translation between clinical trials and real-world? How can we design a comprehensive and systematic approach to explore the grade of translation? Does the approach work in a challenging real-world case study such as small cell lung cancer chemotherapy?

What does this study add to our knowledge?
Differences in operations and protocols have a relevant impact on the gap in clinical outcomes. These must be studied in concomitance with the selection criteria of the baselines. Previous works proposed pure empirical approaches (such as propensity score), and limitations of the findings can be related to the lack of consideration of operational differences between trials and real-world practice. Our approach allowed novel insights regarding which aspects would benefit from further investigation to improve the design of small cell lung cancer studies (ECOG 2 underrepresentation and pre-trial biases, exploring the therapies with the new TNM staging categories, operational biases of trials censoring and progress free survival)

How might this change clinical pharmacology or translational science?
Designing a comprehensive and systematic approach to investigate how selection criteria and operations are impacting on the measurements of outcome would allow us to estimate the trade-off between internal validity and generalizability of clinical trials. Thus, pushing real-world evidence towards a learn and confirm cycle from which we learn case by case and close the translational gap between clinical trials and real-world populations.

Acknowledgments
This project is a contribution to the Centre for Data-Driven Health (CDDH), KTH Royal Institute of Technology (https://www.kth.se/sv/cddh).

Authors Contribution
L.M. and A.S.D. wrote the manuscript. L.M., A.S.D., A.D., S.T., J.R., and S.M. designed the research. L.M., A.S.D., S.T., A.D., R.L., and L.D.P. performed the research. L.M., A.S.D., S.T., A.D., R.L., and L.D.P. analyzed the data

References

1. Beaulieu-Jones, B. K. *et al.* Examining the Use of Real-World Evidence in the

   Regulatory Process. *Clinical Pharmacology & Therapeutics* **107**, 843–852 (2020).

2. Franklin, J. M. & Schneeweiss, S. When and How Can Real World Data Analyses

   Substitute for Randomized Controlled Trials? *Clinical Pharmacology &*

   Therapeutics **102**, 924–933 (2017).

3. Schurman, B. The Framework for FDA's Real-World Evidence Program. *Applied*

   Clinical Trials **28**, 15–17 (2019).

4. Dagenais, S., Russo, L., Madsen, A., Webster, J. & Becnel, L. Use of Real-World

Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design.

Clinical Pharmacology & Therapeutics **111**, 77–89 (2022).

5. Burns, L. *et al.* Real-World Evidence for Regulatory Decision-Making: Guidance

From Around the World. *Clinical Therapeutics* **44**, 420–437 (2022).

6. Baumfeld Andre, E. *et al.* The Current Landscape and Emerging Applications for

Real-World Data in Diagnostics and Clinical Decision Support and its Impact on

Regulatory Decision Making. *Clinical Pharmacology & Therapeutics* **112**, 1172–

1182 (2022).

7. Campbell, U. B., Honig, N. & Gatto, N. M. SURF: A Screening Tool (for

Sponsors) to Evaluate Whether Using Real-World Data to Support an

Effectiveness Claim in an FDA Application Has Regulatory Feasibility. *Clinical*

Pharmacology & Therapeutics **114**, 981–993 (2023).

8. Wang, C. Y. *et al.* Uncontrolled Extensions of Clinical Trials and the Use of

External Controls—Scoping Opportunities and Methods. *Clinical Pharmacology*

& Therapeutics **111**, 187–199 (2022).

9. Wang, S. V. *et al.* Reproducibility of real-world evidence studies using clinical

practice data to inform regulatory and coverage decisions. *Nature*

Communications **13**, 1–11 (2022).

10. Jemielita, T. *et al.* Replication of Oncology Randomized Trial Results using

Swedish Registry Real World-Data: A Feasibility Study. *Clinical Pharmacology*

& Therapeutics **110**, 1613–1621 (2021).

11. Sreeram V. Ramagopalan, Ramagopalan, S. V., Ramagopalan, S. V., Simpson, A.

& Sammon, C. J. Can real-world data really replace randomised clinical trials?

BMC Medicine **18**, 13–13 (2020).

12. Lin, J., Liao, R. & Gamalo-Siebers, M. Dynamic incorporation of real world

evidence within the framework of adaptive design. *J Biopharm Stat* **32**, 986–998

(2022).

13. He, Z. *et al.* Clinical Trial Generalizability Assessment in the Big Data Era: A

Review. *Clinical and Translational Science* **13**, 675–684 (2020).

14. Tan, K. *et al.* Emulating Control Arms for Cancer Clinical Trials Using External

Cohorts Created From Electronic Health Record-Derived Real-World Data.

Clinical Pharmacology & Therapeutics **111**, 168–178 (2022).

15. Franklin, J. M., Glynn, R. J., Martin, D. & Schneeweiss, S. Evaluating the Use of

Nonrandomized Real-World Data Analyses for Regulatory Decision Making.

Clinical Pharmacology & Therapeutics **105**, 867–877 (2019).

16. Franklin, J. M. *et al.* Nonrandomized Real-World Evidence to Support Regulatory

Decision Making: Process for a Randomized Trial Replication Project. *Clinical*

pharmacology and therapeutics **107**, 817–826 (2020).

17. Bartlett, V., Dhruva, S., Shah, N., Ryan, P. & Ross, J. Feasibility of Using Real-

World Data to Replicate Clinical Trial Evidence. *JAMA NETWORK OPEN* **2**,

(2019).

18. Abrahami, D. *et al.* Use of Real-World Data to Emulate a Clinical Trial and

Support Regulatory Decision Making: Assessing the Impact of Temporality,

Comparator Choice, and Method of Adjustment. *Clinical Pharmacology &*

Therapeutics **109**, 452–461 (2021).

19. Ho, M. *et al.* Examples of Applying RWE Causal-Inference Roadmap to Clinical

Studies. *STATISTICS IN BIOPHARMACEUTICAL RESEARCH* (2023)

doi:10.1080/19466315.2023.2177333.

20. Stewart, M. *et al.* An Exploratory Analysis of Real-World End Points for

Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced

Non–Small-Cell Lung Cancer. *JCO Clinical Cancer Informatics* 1–15 (2019)

doi:10.1200/cci.18.00155.

21. Oksen, D. *et al.* Treatment effectiveness in a rare oncology indication: Lessons

from an external control cohort study. *Clinical and Translational Science* **15**,

1990–1998 (2022).

22. Rivera, D. R. *et al.* The Friends of Cancer Research Real-World Data

Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case

Studies. *Clinical Pharmacology & Therapeutics* **111**, 283–292 (2022).

23. Cramer-van der Welle, C. M. *et al.* Real-world outcomes versus clinical trial

results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the

Netherlands. *Scientific Reports* **11**, 6306 (2021).

24. Lakdawalla, D. N. *et al.* Predicting Real-World Effectiveness of Cancer Therapies

Using Overall Survival and Progression-Free Survival from Clinical Trials:

Empirical Evidence for the ASCO Value Framework. *Value in Health* **20**, 866–

875 (2017).

523 25. Lasiter, L. *et al.* Real-world Overall Survival Using Oncology Electronic Health

524 Record Data: Friends of Cancer Research Pilot. *Clinical Pharmacology &*

525 *Therapeutics* **111**, 444–454 (2022).

526 26. Loureiro, H. *et al.* Matching by OS prognostic score to construct external controls

527 in lung cancer clinical trials. *Clinical Pharmacology & Therapeutics* **n/a**,.

528 27. Webster-Clark, M. *et al.* Using propensity scores to estimate effects of treatment

529 initiation decisions: State of the science. *Statistics in Medicine* **40**, 1718–1735

530 (2021).

531 28. Rosenbaum, P. R. & Rubin, D. B. The central role of the propensity score in

532 observational studies for causal effects. *Biometrika* **70**, 41–55 (1983).

533 29. Loureiro, H., Becker, T., Bauer-Mehren, A., Ahmidi, N. & Weberpals, J. Artificial

534 Intelligence for Prognostic Scores in Oncology: a Benchmarking Study. *Frontiers*

535 *in artificial intelligence* **4**, (2021).

536 30. Liu, R. *et al.* Evaluating eligibility criteria of oncology trials using real-world data

537 and AI. *Nature* **592**, 629–633 (2021).

538 31. Franklin, J. *et al.* Emulating Randomized Clinical Trials With Nonrandomized

539 Real-World Evidence Studies First Results From the RCT DUPLICATE Initiative.

540 *CIRCULATION* **143**, 1002–1013 (2021).

541 32. Feinberg, B. A. *et al.* Use of Real-World Evidence to Support FDA Approval of

542 Oncology Drugs. *Value in Health* **23**, 1358–1365 (2020).

543 33. Bolislis, W. R., Fay, M. & Kühler, T. C. Use of Real-world Data for New Drug

544 Applications and Line Extensions. *Clinical Therapeutics* **42**, 926–938 (2020).

34. Wang, Y. *et al.* Model-Informed Drug Development: Current US Regulatory

Practice and Future Considerations. *Clinical Pharmacology & Therapeutics* **105**,

899–911 (2019).

35. Greenhalgh, T. & Papoutsi, C. Studying complexity in health services research:

desperately seeking an overdue paradigm shift. *BMC Medicine* **16**, 95 (2018).

36. Tendler, S. *et al.* Treatment patterns and survival outcomes for small-cell lung

cancer patients - a Swedish single center cohort study. *Acta Oncol* **59**, 388–394

(2020).

37. Green, A. K. *et al.* The Project Data Sphere Initiative: Accelerating Cancer

Research by Sharing Data. *The Oncologist* **20**, 464-e20 (2015).

38. Tendler, S. *et al.* Validation of the 8th TNM classification for small-cell lung

cancer in a retrospective material from Sweden. *Lung Cancer* **120**, 75–81 (2018).

39. Chawla, N. V., Bowyer, K. W., Hall, L. O. & Kegelmeyer, W. P. SMOTE:

Synthetic Minority Over-sampling Technique. *Journal of Artificial Intelligence*

Research **16**, 321–357 (2002).

40. Pietanza, M. C., Byers, L. A., Minna, J. D. & Rudin, C. M. Small Cell Lung

Cancer: Will Recent Progress Lead to Improved Outcomes? *Clinical Cancer*

Research **21**, 2244–2255 (2015).

41. Jaoude, J. A. *et al.* Performance Status Restriction in Phase III Cancer Clinical

Trials. *Journal of the National Comprehensive Cancer Network : JNCCN* **18 10**,

1322–1326 (2020).

42. Pang, H. H. *et al.* Enrollment Trends and Disparity Among Patients With Lung

Cancer in National Clinical Trials, 1990 to 2012. *JCO* **34**, 3992–3999 (2016).

43. Hutchins, L. F., Unger, J. M., Crowley, J. J., Coltman, C. A. & Albain, K. S.

Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment

Trials. *New England Journal of Medicine* **341**, 2061–2067 (1999).

44. Hwang, J. K. *et al.* Validation of the Eighth Edition TNM Lung Cancer Staging

System. *Journal of Thoracic Oncology* **15**, 649–654 (2020).

45. Marzano, L. *et al.* A novel analytical framework for risk stratification of real-

world data using machine learning: A small cell lung cancer study. *Clinical and*

Translational Science **00**, 1–11 (2022).

46. Tan, F. *et al.* External validation of the eighth edition of the TNM classification

for lung cancer in small cell lung cancer. *Lung Cancer* **170**, 98–104 (2022).

47. Gilboa, S. *et al.* Informative censoring of surrogate end-point data in phase 3

oncology trials. *Eur J Cancer* **153**, 190–202 (2021).

48. Shebley, M. *et al.* Physiologically Based Pharmacokinetic Model Qualification

and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.

Clinical Pharmacology & Therapeutics **104**, 88–110 (2018).

583
584 **Tables**
585
586 Table 1. SOMO analysis description for mixed cohort SCLC study. RWD: real-world data, RCT:
587 random clinical trial, RECIST: Response evaluation criteria in solid tumors, SMOTENC: Synthetic
588 Minority Over-sampling TEchnique-Nominal Continuous, OS: overall survival, PFS: progress free
589 survival.

SOMO component	Parameter/Factor to investigate	Is possible to investigate using the current data?	Analysis Description
Selection Criteria (S)	ECOG Performance status	Yes	Cohort stratification based on ECOG
	Sex	Yes	Cohort stratification sex
	Age	Yes	Cohort stratification of patients older than 75 years
	Brain Metastasis	Yes Baseline brain metastasis records were not available for	Cohort stratification based on brain metastasis where possible

		all clinical trial patients, or not explicit mentioned as an exclusion criterion.	
	Cancer Stage	Yes For RWD: 8th TNM version ("IVA" PR "IVB"). For RCTs: VALSG stage (unique value:" ED-SCLC")	Cohort stratification of RWD TNM staging IVA and IVB Oversampling with SMOTENC of RWD TNM IVA to balance with IVB patients
	RCT selection criteria "probability of survive more than three months"	Yes This information is not explicitly expressed in the RCTs data. We can only find a simulation strategy to reproduce this implicit selection in the RWD	Simulated by matching the RWD patients using a propensity score matching with Y = "OS >90days" (y/n)
	RWD propensity score matching	Yes	Propensity score matching with Y= "probability of being included in the RCT study cohort" (y/n)
	Lab tests and chemistry blood values before initiating the treatment	Few overlaps between RWD and RCTs. The only common baseline available in all the studies was haemoglobin. Few RCTs instances matched with the RWD available blood values (Lactate Dehydrogenase, Albumin, and Sodium)	
	Other Key baselines: smoking status, ethnicity, and comorbidity score	Smoking status: information not available from the RCTs Ethnicity: Information not available from the RWD Co-morbidity score: information not available from RWD and RCTs	
Operations and protocols (O)	Outcomes definition Correction (RWD survival outcomes are calculated from the start of the therapy, RCTs from the randomisation)	Yes Correction made from the RCTs data when timestamps were available. For the RCTs with this information missing, we imputed the correction as random effect informed by the available one.	Analysis performed with the corrected RCTs outcomes

	ECOG 2 RCT pre-trial enrolment bias.	Yes RCT patients with ECOG 2 were compared with RWD ECOG 2-3 to assess of there was a worsening of baseline for the RCTs patients.	Sub-cohort stratification.
	Clinical trials censoring	Yes	Inclusion the censored records for futility of the PDS_EliLilly study to estimate the censoring bias Removing all censored patients from the analysis Propensity score matching including the censoring as variable.
	Variability and robustness of the longitudinal profile of survival curves difference.	Yes	Creation a real-world synthetic cohort with same RCTs sample size using SMOTENC oversampling and simulating censoring effect with same distribution of the clinical trials
	Treatment administration (e.g., dose-response variables)	Information not available from the RWD	
	Longitudinal biomarkers, and lab test or chemistry values	Information not available from RWD	
	Longitudinal events and intermediate decisions (e.g., tumour regression, adherence to therapy, radiological progression, worsening of patient status)	Information not available from RWD	
	RECIST assessment of the radiological processes	Information not available from RWD. RECIST assessment is performed systematically in RCTs, but no in RWD.	
	Treatment lines after first line therapy	Information not available from RCTs	

	Survival outcomes: Overall Survival (OS) and Progress Free Survival (PFS)	Yes PFS is not available for all the RCTs data	Common reported outcomes. Analysis with Kaplan Meier Curves, and Cox Hazard ratios of the entire cohort hazard ratio variability. Hazard ratios distribution obtained from the pairwise matching simulation of interventions on the matching (Figure S1)
Measurements of Outcome (MO)	Toxicity analysis (Adverse Effects incidence, toxicity grade)	Information not available from RWD	

590
591
592 Table 2. Summary of the most important results for the aggregated cohort analysis. The log-
593 rank test of Kaplan Meier Curves confirmed the results obtained with the Cox Hazard ratios[1]

Measurement of outcome (MO)	Parameter analysis	Total Cohort (RCT, RWD)	Hazard Ratio (ref=RWD)
Overall Survival	Baseline MO difference	1224 (996, 228)	0.65 [0.55-0.75]***
	(S) ECOG 0	386 (331, 55)	0.71 [0.52-0.97]*
	(S) ECOG 1	669 (564, 105)	0.75 [0.6-0.94]*
	(S) ECOG 2	**169 (101, 68)**	**0.73 [0.53-1]**
	(S) TNM staging STRAT	**1224 (996, IVA:40 IVB: 188)**	**IVA: (ref), IVB: 1.9 [1.36-2.7]***, RCT: 1.1 [0.78-1.5]**
	(S) Oversampling TNM-IVA stage	**1372 (996, IVA: 188 IVB: 188)**	**IVA: (ref), IVB: 1.72 [1.40-2.1]***, RCT: 0.96 [0.81-1.1]**
	(O) Propensity score including also the censoring as variable	**456 (228, 228)**	**1.1 [0.87-1.3]**
	(O) Oversampling RWD simulating RCT censoring	1992 (996, 996)	0.89 [0.8-0.99]*
Progress Free Survival	Baseline MO difference	689 (461, 228)	0.7 [0.58-0.85]***
	(S) ECOG 0	**261 (206, 55)**	**0.78 [0.54-1.1]**
	(S) ECOG 1	**330 (225, 105)**	**0.85 [0.64-1.1]**
	(S) ECOG 2	**98 (30, 68)**	**1.2 [0.74-2]**

---

[1] Bold text: detected similarity of outcomes, Underlined text: detected switch of survival outcome (better prognosis for real-world patients). (S): selection criteria, (O): operations, (MO): measurement of outcomes, RCT: randomize controlled trials, RWD: real-world data. For the hazard ratios is reported the 95% confidence level interval. (*) p-value<0.05, (**) p<0.01, (***) p<0.001

	(S) TNM staging STRAT	689 (461, IVA: 40, IVB: 188)	IVA: (ref), IVB: 1.7 [1.21-2.5]**, RCT: 1.1 [0.76-1.6]
	(S) Oversampling TNM-IVA stage	837 (461, IVA: 188, IVB:188)	IVA: (ref), IVB: 1.6 [1.26-1.9]**, RCT 1.0 [0.81-1.2]
	(O) ECOG 2 pre-trial effect	216 (ECOG 2 RCT: 101, ECOG 2 RWD: 169; ECOG 3 RWD: 47)	ECOG 2 RCT: (ref), ECOG 2 RWD: 0.79 [0.48-1.3] , ECOG 3 RWD: 1.26 [0.74-2.1]
	(O) Including censored records for study futility	772 (544, 228)	0.67 [0.56-0.81]***
	(O) Removing all censored patients	433 (210, 223)	1.5 [1.2-1.8]***
	(O) Propensity score including also the censoring as variable	456 (228, 228)	1.5 [1.2-1.8]***
	(O) Oversampling RWD simulating RCT censoring	922 (461, 461)	1.5 [1.2-1.8]***

594
595
596
597
598   **Figures**
599

Figure 1. Summary description of the SOMO approach. Data are retrieved and pre-processes (step a), explorative analysis (step b), estimating the impact of factors on translation between cohorts (step c), validation and evaluation of the results (step d).

604
605 **Figure 2.** Overall Survival Kaplan Meier Curves and number of censored patients across the time for
606 the a) baseline survival gap of measurement of outcome (n=1224), b) synthetic oversampled RWD
607 cohort with same trial censoring (n=1992). The cohort in b) was obtained by oversampling RWD with
608 the SMOTENC algorithm to match RCT sample size, and simulating RWD censoring using the same
609 distribution of the RCT cohort. RWD: real-world data.
610

611
612 **Figure 3.** Overall Survival Kaplan Meier Curves using a) traditional propensity score marching
613 (n=456), and b) propensity score accounting trials censoring (n=456). RWD: real-world data.

614
615 **Figure 4.** Matching Simulation results for overall survival hazard ratios for PDS_EliLilly and
616 PDS_Amgen. Strat.: stratification, BM: brain metastases, PR.SC.: propensity score, RWD: real-world
617 data. Hazard ratio and 95% confidence level interval with the whole cohort is reported in red dotted
618 lines.
619

620
621 **Figure 5.** Matching Simulation results for progress free survival hazard ratios for PDS_EliLilly.
622 Strat.: stratification, BM: brain metastases, PR.SC.: propensity score, RWD: real-world data. Hazard
623 ratio and 95% confidence level interval with the whole cohort is reported in red dotted lines.
624

625 **Supplementary information Titles**
626 • Supplementary Materials for Methods section
627 • Supplementary Materials for Results section
628
629